Structural basis of human CYP51 inhibition by antifungal azoles

Journal of Molecular Biology

Volumn 397, Issue 4, 2010, Pages 1067-1078

  Strushkevich, Natallia ^a   Usanov, Sergey A ^b   Park, Hee Won ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Belarus)

Author keywords

Antifungal drugs; Human cytochrome P450; Sterol 14alpha demethylase; X ray crystallography

Indexed keywords

1 PHENYLIMIDAZOLE; 4 PHENYLIMIDAZOLE; ANTIFUNGAL AGENT; BIFONAZOLE; CLOTRIMAZOLE; CYPROCONAZOLE; ECONAZOLE; FLUCONAZOLE; KETOCONAZOLE; LANOSTEROL; MICONAZOLE; PROPICONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TRIADIMENOL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME STRUCTURE; HUMAN; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BACTERIA (MICROORGANISMS); EUKARYOTA; MAMMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 77950023120     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.01.075     Document Type: Article

References (53)

1. Aoyama Y. Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. Front. Biosci. 2005, 10:1546-1557.
2. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999, 12:40-79.
3. Kale P., Johnson L.B. Second-generation azole antifungal agents. Drugs Today 2005, 41:91-105.
4. Roberts C.W., McLeod R., Rice D.W., Ginger M., Chance M.L., Goad L.J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 2003, 126:129-142.
5. Mishra J., Saxena A., Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem. 2007, 14:1153-1169.
6. Marichal P., Koymans L., Willemsens S., Bellens D., Verhasselt P., Luyten W., et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999, 145(Pt. 10):2701-2713.
7. Loffler J., Kelly S.L., Hebart H., Schumacher U., Lass-Florl C., Einsele H. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 1997, 151:263-268.
8. Cools H.J., Fraaije B.A., Kim S.H., Lucas J.A. Impact of changes in the target P450 CYP51 enzyme associated with altered triazole-sensitivity in fungal pathogens of cereal crops. Biochem. Soc. Trans. 2006, 34:1219-1222.
9. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
10. Burton P.M., Swinney D.C., Heller R., Dunlap B., Chiou M., Malonzo E., et al. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem. Pharmacol. 1995, 50:529-544.
11. Mayer R.J., Adams J.L., Bossard M.J., Berkhout T.A. Effects of a novel lanosterol 14 alpha-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in Hep G2 cells. J. Biol. Chem. 1991, 266:20070-20078.
12. Frye L.L., Leonard D.A. Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Crit. Rev. Biochem. Mol. Biol. 1999, 34:123-140.
13. Harwood H.J., Petras S.F., Hoover D.J., Mankowski D.C., Soliman V.F., Sugarman E.D., et al. Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase. J. Lipid Res. 2005, 46:547-563.
14. Korosec T., Acimovic J., Seliskar M., Kocjan D., Tacer K.F., Rozman D., Urleb U. Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51). Bioorg. Med. Chem. 2008, 16:209-221.
15. Yoshida Y., Yamashita C., Noshiro M., Fukuda M., Aoyama Y. Sterol 14-demethylase P450 activity expressed in rat gonads: contribution to the formation of mammalian meiosis-activating sterol. Biochem. Biophys. Res. Commun. 1996, 223:534-538.
16. Byskov A.G., Andersen C.Y., Nordholm L., Thogersen H., Xia G., Wassmann O., et al. Chemical structure of sterols that activate oocyte meiosis. Nature 1995, 374:559-562.
17. Stromstedt M., Waterman M.R., Haugen T.B., Tasken K., Parvinen M., Rozman D. Elevated expression of lanosterol 14alpha-demethylase (CYP51) and the synthesis of oocyte meiosis-activating sterols in postmeiotic germ cells of male rats. Endocrinology 1998, 139:2314-2321.
18. Marin Bivens C.L., Grondahl C., Murray A., Blume T., Su Y.Q., Eppig J.J. Meiosis-activating sterol promotes the metaphase I to metaphase II transition and preimplantation developmental competence of mouse oocytes maturing in vitro. Biol. Reprod. 2004, 70:1458-1464.
19. Grondahl C., Breinholt J., Wahl P., Murray A., Hansen T.H., Faerge I., et al. Physiology of meiosis-activating sterol: endogenous formation and mode of action. Hum. Reprod. 2003, 18:122-129.
20. Cotman M., Jezek D., Fon Tacer K., Frangez R., Rozman D. A functional cytochrome P450 lanosterol 14 alpha-demethylase CYP51 enzyme in the acrosome: transport through the Golgi and synthesis of meiosis-activating sterols. Endocrinology 2004, 145:1419-1426.
21. Rozman D., Seliskar M., Cotman M., Fink M. Pre-cholesterol precursors in gametogenesis. Mol. Cell. Endocrinol. 2005, 234:47-56.
22. Grondahl C. Oocyte maturation. Basic and clinical aspects of in vitro maturation (IVM) with special emphasis of the role of FF-MAS. Dan. Med. Bull. 2008, 55:1-16.
23. Podust L.M., Poulos T.L., Waterman M.R. Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl Acad. Sci. USA 2001, 98:3068-3073.
24. Aoyama Y., Horiuchi T., Gotoh O., Noshiro M., Yoshida Y. CYP51-like gene of Mycobacterium tuberculosis actually encodes a P450 similar to eukaryotic CYP51. J. Biochem. 1998, 124:694-696.
25. McLean K.J., Dunford A.J., Sabri M., Neeli R., Girvan H.M., Balding P.R., et al. CYP121, CYP51 and associated redox systems in Mycobacterium tuberculosis: towards deconvoluting enzymology of P450 systems in a human pathogen. Biochem. Soc. Trans. 2006, 34:1178-1182.
26. Pechurskaya T.A., Harnastai I.N., Grabovec I.P., Gilep A.A., Usanov S.A. Adrenodoxin supports reactions catalyzed by microsomal steroidogenic cytochrome P450s. Biochem. Biophys. Res. Commun. 2007, 353:598-604.
27. 5. Arch. Biochem. Biophys. 2001, 395:78-84.
28. Trzaskos J., Kawata S., Gaylor J.L. Microsomal enzymes of cholesterol biosynthesis. Purification of lanosterol 14 alpha-methyl demethylase cytochrome P-450 from hepatic microsomes. J. Biol. Chem. 1986, 261:14651-14657.
29. Min L., Strushkevich N.V., Harnastai I.N., Iwamoto H., Gilep A.A., Takemori H., et al. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J. 2005, 272:5832-5843.
30. Rohe H.J., Ahmed I.S., Twist K.E., Craven R.J. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol. Ther. 2009, 121:14-19.
31. McLean K.J., Munro A.W. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis. Drug Metab. Rev. 2008, 40:427-446.
32. Ouellet H., Podust L.M., de Montellano P.R. Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J. Biol. Chem. 2008, 283:5069-5080.
33. Lepesheva G.I., Virus C., Waterman M.R. Conservation in the CYP51 family. Role of the B′ helix/BC loop and helices F and G in enzymatic function. Biochemistry 2003, 42:9091-9101.
34. Bellamine A., Lepesheva G.I., Waterman M.R. Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J. Lipid Res. 2004, 45:2000-2007.
35. Podust L.M., Yermalitskaya L.V., Lepesheva G.I., Podust V.N., Dalmasso E.A., Waterman M.R. Estriol bound and ligand-free structures of sterol 14alpha-demethylase. Structure 2004, 12:1937-1945.
36. Ekroos M., Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl Acad Sci. USA 2006, 103:13682-13687.
37. Cupp-Vickery J.R., Garcia C., Hofacre A., McGee-Estrada K. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J. Mol. Biol. 2001, 311:101-110.
38. Lepesheva G.I., Zaitseva N.G., Nes W.D., Zhou W., Arase M., Liu J., et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B′ helix defines substrate preferences of sterol 14alpha-demethylase. J. Biol. Chem. 2006, 281:3577-3585.
39. Powl A.M., East J.M., Lee A.G. Heterogeneity in the binding of lipid molecules to the surface of a membrane protein: hot spots for anionic lipids on the mechanosensitive channel of large conductance MscL and effects on conformation. Biochemistry 2005, 44:5873-5883.
40. Dowhan W., Bogdanov M. Lipid-dependent membrane protein topogenesis. Annu. Rev. Biochem. 2009, 78:515-540.
41. Boyd D., Beckwith J. The role of charged amino acids in the localization of secreted and membrane proteins. Cell 1990, 62:1031-1033.
42. Williams P.A., Cosme J., Sridhar V., Johnson E.F., McRee D.E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell 2000, 5:121-131.
43. Strushkevich N., Usanov S.A., Plotnikov A.N., Jones G., Park H.W. Structural analysis of CYP2R1 in complex with vitamin D3. J. Mol. Biol. 2008, 380:95-106.
44. Mast N., White M.A., Bjorkhem I., Johnson E.F., Stout C.D., Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl Acad Sci. USA 2008, 105:9546-9551.
45. Ghosh D., Griswold J., Erman M., Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009, 457:219-223.
46. Lepesheva G.I., Park H.W., Hargrove T.Y., Vanhollebeke B., Wawrzak Z., Harp J.M., et al. Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. J. Biol. Chem. 2010, 285:1773-1780.
47. von Wachenfeldt C., Richardson T.H., Cosme J., Johnson E.F. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch. Biochem. Biophys. 1997, 339:107-114.
48. Otwinovski Z. Processing of X-ray diffraction data collection in oscillation mode. Methods. Enzymol. 1997, 276:307-326.
49. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
50. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 1991, 47(Pt. 2):110-119.
51. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53:240-255.
52. Trosken E.R., Straube E., Lutz W.K., Volkel W., Patten C. Quantitation of lanosterol and its major metabolite FF-MAS in an inhibition assay of CYP51 by azoles with atmospheric pressure photoionization based LC-MS/MS. J. Am. Soc. Mass. Spectrom. 2004, 15:1216-1221.
53. Laskowski R.A., MacArthur M.W, Moss D.S., Thornton J.M. PROCHECK-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.